डॉ.राजीव सिंह रघुवंशी
औषधि महानियंत्रक (भारत)
केंद्रीय औषधि मानक नियंत्रण संगठन
स्वास्थ्य एवम परिवार कल्याण मंत्रालय
भारत सरकार
एफ.डी.ए. भवन, कोटला रोड,
नई दिल्ली–110002

सत्यमेव जयते

Dr. Rajeev Singh Raghuvanshi
Drugs Controller General (India)
Central Drugs Standard Control Organisation
Ministry of Health & Family Welfare
Government of India
FDA Bhawan, Kotla Road
New Delhi-110002 (India)

F. No. DC-DT-14011(11)/2/2026-eoffice
Comp. No. 36705

Dated: 07.07.2026

To

All State/ UT Drugs Controllers

Sub: Minutes of the 69th Meeting of the Drugs Consultative Committee (DCC) held on 24.06.2026 through Hybrid mode - reg.

Sir/Madam,

69th meeting of the Drugs Consultative Committee was held on 24.06.2026 through Hybrid mode.

The minutes of the 69th meeting of the Drugs Consultative Committee are annexed herewith for your kind information and taking further necessary action, wherever required, as per recommendations decided therein.

Yours faithfully,

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)

Encl. Copy of the minutes

Copy for information to:-

1. PPS to Secretary, MoHFW, Kartavya Bhawan-1, New Delhi
2. PS to JS(R), MoHFW, Kartavya Bhawan-1, New Delhi
3. DDC (I) of Zonal & Sub-Zonal offices
4. Directors of Labs of CDSCO
5. CDSCO website

MINUTES OF 69th MEETING (HYBRID MODE) OF DRUGS CONSULTATIVE COMMITTEE (DCC)

HELD ON 24th June 2026 AT CDSCO (HQ), FDA BHAWAN, KOTLA ROAD, NEW DELHI – 110002

INAUGURAL DELIBERATIONS

Dr. Rajeev Singh Raghuvanshi, Drugs Controller General (India), Chairman, Drugs Consultative Committee (DCC), welcomed all the members of the committee and appreciated the cooperation received from States from time to time.

The DCG(I) in his opening remarks stressed the need to reinforce the nation's drug regulatory system and expressed appreciation for the coordinated efforts of all the States.

The DCGI urged all States/UTs that have not yet on boarded to join the ONDLS portal at the earliest, to ensure uniformity in the country's inspection and licensing system.

Further, DCC deliberated the agenda items one by one. The list of participants is annexed.

The details of the deliberation and recommendations are as follows:

AGENDA NO.1

Action Taken Report of 68th DCC meeting held on 20.03.2026

The Drugs Consultative Committee deliberated the Action Taken Report (ATR) of the agenda items of the 68th DCC meeting held on 20.03.2026, and the Action Taken Report was considered as approved.

However, DCC was apprised specifically about Agenda No. 6 of ATR i.e constitution of the **sub-committee** to evaluate the issue with respect to enabling of Notified Bodies to conduct periodic planned audits of drug manufacturing, clinical trial, laboratories and blood center sites and **sub-committee** for amending the proposal regarding replacing approval under Form 29 from State FDA for examination, test or analysis with a notification-based system as well as Retail Pharmacy deregulation.

The Chairman of both the sub-committees were requested to expedite the matter. However, DDC (West Zone) requested nominating another Chairman for DCC sub-committee as presently Drugs Controller, Maharashtra is not in position.

AGENDA NO. 2 and AGENDA NO. 3

2. Proposal for Consideration of a Comprehensive Regulatory Mechanism to stop the availability of Unapproved Drugs, including FDCs.

3. Proposal to update the database with respect to Drugs approved by CDSCO but not reflected in the CDSCO database, and to prepare a database of drugs that were licensed by the SLAs prior to 21.09.1988

DCC was apprised of both agendas as above. The matter was deliberated at length. DCC discussed on various actions taken by the Government, including the issuance of directions under Section 33P, etc., to resolve the issue; however, these efforts have not translated into sustained compliance, and therefore, there is a need for a comprehensive regulatory framework to address these issues, as these unapproved drugs can pose a risk to the patients.

DCC, after discussions, opined that any formulation not appearing either on the CDSCO List or listed in I.P. 2010 or its earlier edition may be deemed as unapproved. The competent authority may take appropriate measures, including cancellation of the license, market withdrawal, against such unapproved products.

DCC, after detailed discussion, recommended that a **sub-committee** be formed to examine the issues in totality and to suggest the regulatory measures that can be taken to resolve these issues once and for all, so that a comprehensive database of approved drugs can be made, and necessary action can be taken for the prohibition of drugs that do not fall under such a database.

Further to address the issue of online submission permanently, the DCC recommended that the Drugs Rules may be amended to make submission of all applications on ONDLS in line with the Medical Device Rules, 2017, after due diligence.

Report of the sub-committee may be placed before DCC for further deliberation.

AGENDA NO. 4

Proposal for incorporation of Provisions for Mandatory E-Raktkosh and EQAS for Whole Human Blood and Blood Components under the Drugs Rules

DCC was apprised about the agenda for Mandatory Registration of Licensed Blood Centres on the e-RaktKosh Portal and participation in External Quality Assessment Schemes (EQAS), as Blood transfusion safety remains a critical component of public health.

DCC was further informed that EQAS participation is recommended but lacks explicit enforceability under statutory provisions.

Hence, in view of evolving global best practices and patient safety requirements, DCC deliberated the need to incorporate specific provisions in the Drugs Rules.

DCC, after detailed deliberation, recommended making necessary provisions under the Drugs Rules for mandating the registration of blood centres on the e-Raktkosh portal

DCC also recommended the constitution of a sub-committee to discuss the modalities of EQAS and biometric authentication of the Blood donors in the Blood Centres/camps.

Report of the sub-committee may be placed before DCC for further deliberation.

Further, DCC also recommended that the applications for the renewal of Blood Centers licenses should be attended timely to ensure the provision of renewed licenses.

AGENDA NO. 5

Proposal for Regulation of Manufacturers and Suppliers of Printed Pharmaceutical Packaging Materials to Prevent Illicit Diversion and Misuse in Spurious and Counterfeit Drug Circulation, and to Safeguard Public Health and Supply Chain Integrity.

DCC was apprised about a proposal to introduce an online registration framework for manufacturers/suppliers of printed pharmaceutical packaging materials used for drugs.

The matter was deliberated, and it was recommended to constitute a **sub-committee** to evaluate the feasibility of the proposal for introducing an online registration framework for manufacturers/suppliers of printed pharmaceutical packaging materials used for drugs in light of the definition of “drug” and “manufacture” under the Drugs and Cosmetics Act, 1940. Sub-committee may also invite experts from industry, including the packaging industry, and if required, the opinion of a legal expert may also be taken. The sub-committee may give its report on:

1. The necessity and feasibility of such registration;
2. To suggest an appropriate regulatory framework for insertion under the Drugs Rules, 1945, by way of amendment.
3. Any other measures considered necessary to prevent diversion and misuse of pharmaceutical packaging materials in the manufacture and circulation of spurious and counterfeit drugs, if such regulation is not feasible.

Report of the sub-committee may be placed before DCC for further deliberation.

AGENDA NO. 6

Consideration of the report of the DCC Sub-committee to ensure that safe and pharmaceutical inactive bulks imported /manufactured are used in drug formulations.

DCC was apprised about the importance of control of pharmaceutical excipients w.r.t their quality specification as they are directly used in the manufacturing of formulations.

The matter was earlier deliberated in the 62nd meeting held on 26.09.2023, when it was recommended to constitute a Sub-committee to examine the issue and submit a comprehensive report in the matter. The sub-committee was initially constituted vide O.M. no. Enforc-11015(12)/13/2023 dated 14.11.2023 and thereafter it was re-constituted vide O.M. no. Enforc-11015(12)/13/2023 dated 27.06.2025. Now, the Sub-committee has submitted its report on 04.11.2025.

The key recommendations of the **sub-committee** were discussed, and it was recommended to frame an appropriate regulatory framework for insertion under the Drugs Rules, 1945, by way of amendment.

AGENDA NO. 7

Proposal for Clarification regarding processing and approval/permission of changes in Competent Technical Staff (CTS) under CLAA-approved Large Volume Parenteral (LVP) Manufacturing Licences granted in Form 28-D.

DCC was apprised about a representation received from State Licensing Authority, Himachal Pradesh regarding whether any change for addition, deletion, or replacement of Competent Technical Staff (CTS) under Large Volume Parenteral (LVP) manufacturing licence in Form 28-D requires approval from the Central Licence Approving Authority (CLAA) or can be processed by the concerned State Licensing Authority (SLA) as per Condition 3 of the Licence in Form 28-D and Rule 76 of Drugs Rules 1945.

DCC, after detailed deliberation, clarified that the rule position is very clear and the existing procedure followed by the States/UTs shall continue.

Further, the procedure for a change in technical staff may be digitized on ONDLS portal.

ADDITIONAL AGENDA NO. (A-1)

Proposal for public disclosure of all licenses suspended/cancelled by the State Licensing Authorities

DCC was apprised that it has been observed that some manufacturers have been found submitting a photocopy of the original product license for various procurement orders despite the cancellation of their original product license. Further, it has been observed that details related to the cancellation/suspension of licenses are not displayed by states/UTs on their official website for disclosure to the public. It has also been observed that such data is also not shared with CDSCO, which leads to a regulatory disconnect between the Center and States for various regulatory actions and monitoring.

After detailed deliberation, DCC recommended that:

1. Details of cancellation/suspension of license, stop order, recall alert, etc. shall be posted by the concerned SLAs on their official website.
2. Such details shall be shared with CDSCO on a monthly basis before the 10th of every month.
3. All states shall furnish monthly NSQ data in the prescribed format within the stipulated timeline.

In closing remarks, DCG(I) also informed that **I.P. 2026** has come into force on 01.07.2026 and therefore, requested all the states/UT Drugs Controllers to ensure its full and timely implementation by all the stakeholders.

The meeting ended with a vote of thanks to the Chair.

****

LIST OF PARTICIPANTS

List of the participants of 69th Drugs Consultative Committee meeting held on 24.06.2026 through hybrid mode under the Chairmanship of Dr. Rajeev Singh Raghuvanshi, Drugs Controller General (India)

A. State/UTs Drugs Control Organizations

S. No.	State/UT	Name	Designation
1.	Assam	Shri Biswajit Talukdar	Drugs Controller
2.	Bihar	Sh. Nityanad Kishloya	Drugs Controller
3.	Chhattisgarh	Sh. B.R. Sahu	Drugs Controller
4.	Goa	Smt. Swati Lad	Deputy Director
5.	Gujarat	Sh. R. M. Patel	Joint Commissioner
6.	Haryana	Sh. Rakesh Dahiya	Asst. State Drugs Controller
7.	Himachal Pradesh	Dr. Manish Kapoor	Drugs Controller
8.	Jharkhand	Smt. Ritu Sahay	Director (Drugs)
9.	Karnataka	Dr. Bhaskaran J	Deputy Drugs Controller
10.	Kerala	Dr. Sujith Kumar	Drugs Controller
11.	Madhya Pradesh	Sh. Rajesh Jinwal Sh. Dharmesh Bigoniya	Drugs Inspector (Additional charge as LA) Drugs Inspector
12.	Manipur	Sh. Seram Baleshwar Singh	Drugs Licensing Authority
13.	Meghalaya	Mrs Aurelia Rela Kharwanlang	Drugs Controller
14.	Mizoram	Shri. F Lalliantluanga	Drugs Controller
15.	Nagaland	Ethungbemo Ezung	Asst. Drugs Controller
16.	Odisha	Mrs. Mamina Patnaik	Drugs Controller
17.	Punjab	Sh. Sanjeev Kumar	Joint Commissioner (Drugs)
18.	Rajasthan	Shri Ajay Phatak	Drugs Controller
19.	Tamil Nadu	Shri S. Gurubharathi	Deputy Director of Drugs Control
20.	Telangana	Sh. K. Dass	Deputy Director
21.	Tripura	Shri. Subrata Das	State Drugs Controller
22.	Uttarakhand	Sh. Tajber Singh	Drugs Controller

S. No.	State/UT	Name	Designation
23.	West Bengal	Mr Rathindranath Ray	Director Of Drugs Control & LA
24.	Dadar and Nagar Haveli	Dr. Dharmesh Agrawal	Assistant Drugs Controller
25.	Pondicherry	Dr. E. Ananda Kirouchenane	Drugs Controller
26.	Delhi	Sh. Rajeev Bhargava	Deputy Drugs Controller/Controlling Authority
27.	Ladakh	Mrs. Nasreen Bano	ADC Cum Licensing Authority
28.	Jammu and Kashmir	Sh. Rajesh Kumar Angurana	Drugs Controller
29.	Lakshadweep	Shri. Barani DHS	Drugs Controller

B. CDSCO (Head Quarters)

S. No.	Name	Designation
1.	Dr. Rajeev Singh Raghuvanshi	Drugs Controller General of India
2.	Dr. A Visala	Joint Drugs Controller (India)
3.	Sh. Ranga Chandrashekar	Joint Drugs Controller (India)

C. Directors of Laboratories of CDSCO

D. Deputy Drugs Controllers / Assistant Drugs Controllers from Zonal and Sub-zonal offices of CDSCO

E. Deputy Drugs Controllers of CDSCO HQ

F. Special Invitee: - Dr. Jai Prakash, Sr. Principal Scientific Officer, IPC on behalf of Chairman, IPC.

***